Clinical Trial Detail

NCT ID NCT02912754
Title Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients
Recruitment Unknown status
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Sunnybrook Health Sciences Centre
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib

Ibrutinib + Ruxolitinib

Age Groups: senior adult

No variant requirements are available.